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Summary Detailed data and statistics per each morphological site of various digestive neoplasms were
obtained for the period 1976-87 from the Vaud Cancer Registry datafile, a population-based cancer registra-
tion scheme covering about 530,000 inhabitants from the French-speaking part of Switzerland. Tabulations
presented include absolute number of cases (1,041 oral and pharyngeal, 545 oesophageal, 1,131 gastric, 83
small intestine, 1,980 colon, 1,267 rectal, 357 liver, 328 gallbladder and 725 pancreatic cancers), percent
distributions, age-standardised rates, sex ratios and 5-year survival. The report has essentially a descriptive
value, and should be viewed as a contribution towards quantification, in a well surveilled population of the
West-central part of Europe, of the proportional distribution of digestive neoplasms by morphological type,
and corresponding incidence and survival rates. Among the points deserving specific attention, there are the
elevated frequency of upper digestive tract cancers, the very high male-to-female ratios for squamous cell
carcinomas, adenocarcinomas of the oesophagus and hepatocellular carcinomas of the liver, the female
excesses in infiltrating carcinoids of the colon, transitional and squamous cell carcinomas of the rectum and
adenocarcinomas of the gallbladder, and the crossover in male-to-female ratio in squamous cell carcinoma
along the digestive tract (i.e. from 6.0 at the level of the mouth/pharynx to 0.5 in the rectum). As concerns
survival, rates were higher for lymphomas and sarcomas than for carcinomas in oral cavity and stomach,
similar for carcinoids and carcinomas in the small bowel (about 35% at 5 years), as well as for colon (34%)
and rectal (37%) cancers. Some of the findings, such as the higher survival of carcinomas arising from polyps
in the colon and rectum, or the higher proportion of cholangiocellular and combined cholangio- and
hepatocellular carcinomas in females than in males find plausible prognostic or aetiologic correlates, but
others, such as the large proportions of squamous and transitional cell cancers of the rectum in females are
more difficult to explain. These and several other indications emerging from careful examination of the data
herein presented underline the interest of morphological analyses of digestive tract cancers.
In the scientific literature, cancer incidence registration and
death certification statistics are usually reported by major
sites (Muir et al., 1987), while more detailed analyses by
different histotypes or other morphological entities are con-
fined to reports whose circulation is relatively limited.
Such information, however, has potential importance for
epidemiological and clinical research (Faivre et al., 1979a;
Weber et al., 1980; Widgren, 1980; Blenkisopp et al., 1981;
Levine et al., 1981; Mittal et al., 1983; Faivre et al., 1985;
Cherie-Challine et al., 1988; Yang & Davis, 1989; Kimura et
al., 1989). For instance, various histotypes ofthe same cancer
may recognise different aetiologies, and in a study or in a
review of studies on risk factors, it is of interest to compare
the distribution of histological types with that from popu-
lation-based data. Similar problems may emerge in the analy-
sis of clinical trials, since the morphological characteristics of
a tumour may have important implications for evaluation of
survival rates and, more in general, prognosis of the disease.
In the present report, therefore, we present absolute pro-
portions, incidence, sex ratios and survival rates from the
Cancer Registry of the Canton Vaud, Switzerland, for diges-
tive sites, where detailed morphological distinctions and their
variation according to age and sex has potential epidemio-
logical and clinical relevance.
Material and methods
The data included in the present analysis were derived from
the Vaud Cancer Registry datafile, which includes data con-
cerning incident cases of malignant neoplasms in the Canton
(whose population in 1980 was about 530,000 inhabitants)
(Levi, 1987). Population estimates are based on decennial
censuses (1970, 1980), and on estimates by the Cantonal
Office of Statistics for each calendar year and 5 year age
group, based on official numbers of births, deaths, immigra-
tions and emigrations (Service Cantonal de Recherche et
d'Information Statistiques).
Notification is based on a voluntary agreement between
the recording medical institutions of the Canton and the
Registry. All hospitals, pathological laboratories and most
practitioners are asked to report all new or past cases of
cancer. The main source of notification is the Cantonal
University Pathological Department of Lausanne which per-
forms the majority of histological examinations for the popu-
lation covered by the Registry. Most cases are registered
repeatedly and from different institutions, thus ensuring com-
pleteness and accuracy of notification. Cases known only
through the death certificate ('Death Certificate Only' cases
(DCO)) contribute less than 5% of the average number of
new cancer cases registered per year.
Information collected by the registry includes general
demographic characteristics of the patient (age, sex, munici-
pality of residence), site and histological type of the tumour
according to the standard International Classification of
Diseases for Oncology (ICD-O; Worth Health Organization,
1976), and time of registration. A total of 7,457 digestive
invasive cancer cases, registered between 1976 and 1987, were
included in the present study.
Digestive cancer sites and morphologic categories con-
sidered according to the ICD-O Classification are listed in
Table I.
Passive and active follow-up information is recorded and
each subsequent item of information concerning an already
registered case is used to complete the record of that patient.
Information coming from death certificates is routinely added
to the morbidity file. The vital status of each registered case
has thus been verified up to June 30, 1989.
Five-year crude survival probability and corresponding
standard error were computed, for each topographical and
morphological group, by means of the product-limit method
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Table I Morphologic categories of digestive cancer sites considered
according to the International Classification ofDiseases for Oncology
(ICD-O; WHO, 1976)
Site
Morphological typea ICD-O Morphological classificationb
Mouth or pharynx
(ICD-9: 140-149)a
Squamous cell
Adenocarcinoma
Other carcinoma
Sarcoma
Lymphoma
Other or undefined
Oesophagus (ICD-9: 150)
Squamous cell
Adenocarcinoma
Other carcinoma
Other or undefined
Stomach (ICD-9: 151)
Adenocarcinoma
Other carcinoma
Sarcoma
Lymphoma
Other or undefined
807b
814,826,848
801-805
881, 883, 889-892, 913, 958
959-969
800, 808, 820, 843, 855, 856, 872, 999
807
814, 826, 848-849
801 -804
820,843,856,999
814, 819, 821, 826, 831, 848-849, 856
801 -804
880-888
959-969
800,824,999
Small intestine (ICD-9: 152)
Adenocarcinoma 814, 826, 848
Carcinoidc 824
Sarcoma 889
Lymphoma 959-969
Other or undefined 972, 975, 999
Colon (ICD-9: 153)
Adenocarcinoma
Adenocarcinoma in
polyp/polyposis
Other carcinoma
Carcinoidc
Other or undefined
Rectum (ICD-9: 154)
Adenocarcinoma
Adenocarcinoma in
polyp/polyposis
Squamous cell
Transitional cell
Other or undefined
Liver (ICD-9: 155)
Hepatocellular
carcinoma
Cholangiocellular and
combined type
carcinoma
Other or undefined
Gallbladder (ICD-9: 156)
Adenocarcinoma
Squamous cell
Other carcinoma
Other or undefined
Pancreas (ICD-9: 157)
Adenocarcinoma
Islet cell carcinoma
Other carcinoma
Other or undefined
814, 826d, 848-849
821 -822, 826e
801 -805
824
800, 844, 847, 856, 889, 913, 964, 999
814, 848-849
821 -822, 826e
807
812
800-801, 805, 972, 889, 999
817
816, 818
800-801, 814, 848, 880, 897, 913, 999
814, 826, 848-849
807
801-804
800, 843, 856, 857, 889, 999
814, 819, 826, 848-849
815
801-804
800, 807, 844, 850, 856, 959, 999
aInternational Classification of Diseases for Oncology Topographic
three-digit code(ICD-0:T). bIntemational Classification ofDiseases for
Oncology Morphologic three-digit code (ICD-0: M). cOnly infiltrating
carcinoid tumours were considered. dFour-digit ICD-O: M
code = 8260. eFour-digit ICD-O: M code = 8261-3.
(Peto et al., 1977), starting from the date of histological
(diagnostic) confirmation.
Results
Table II gives absolute numbers, percentages and age-stand-
ardized incidence rates (world standard) for each cancer site,
morphological type and sex, and sex ratios (male-to-female)
of age-standardised incidence rates.
A total of 1,041 cases of oral and pharyngeal cancers (826
males and 215 females) were registered, corresponding to
age-standardised rates of 19.8/100,000 males and 3.8/100,000
females. Among them, 85% were squamous cell cancer, 1%
adenocarcinomas, 2.7% lymphomas, 0.4% sarcomas and
about 10% other or undefined types. The histotype distribu-
tion was somewhat heterogeneous in the two sexes, since
squamous cell carcinomas were proportionally more frequent
in males (87%), while lymphomas were in absolute terms
similar in the two sexes, but in proportional terms more
frequent in females. The sex ratio was, therefore, highest for
squamous cell carcinomas (6.0), intermediate for adenocar-
cinomas (2.5) and equal to 1 for lymphomas.
For oesophageal cancer, a total of 545 incident cases were
registered (397 males, 148 females), with incidence rates of
8.9/100,000 males and 2.4/100,000 females. In both sexes,
squamous cell cancers accounted for over 70% of cases, ade-
nocarcinomas for approximately 10% and other and unspeci-
fied histotypes for the remaining 15 to 20%. Herein however
the sex ratio was apparently higher for adenocarcinomas as
compared to squamous cell cancers (i.e., 11.0 vs 3.3).
Among the 1,131 registered cases of stomach cancer (709
males, age-adjusted incidence rate 15.4/100,000; 422 females,
6.0/100,000), over 80% were adenocarcinomas, 5% lympho-
mas and 10% other and unspecified histotypes, these propor-
tions being not appreciably different in the two sexes. Indeed,
with the exception of the very rare sarcomas, the sex ratio was
remarkably similar for each morphologic type, at variance
with what reported for tumours of the mouth and pharynx.
There were 83 cases of small intestine cancer (45 males, 38
females), corresponding to an overall incidence of 0.7/100,000.
Adenocarcinomas and infiltrating carcinoids accounted for
31% of cases each, sarcomas for 10% and lymphomas for
21% approximately (plus 7% other and unspecified), in the
absence ofsignificant differences in the two sexes. Highest sex
ratios were recorded for adenocarcinomas and lymphomas
(3.0 for both).
A total of 1,980 colon cancer cases were registered
(941 males, incidence rate 20.0/100,000; 1,039 females,
incidence rate 14.9/100,000). Adenocarcinoma was by far the
most common histologic type, with 88% of cases in both
sexes, plus 2.8% of adenocarcinomas arising in polyps or
polyposis. There were 12 carcinoids, and over 130 other or
unspecified histotypes. The male excess was moderate
(global sex ratio = 1.2) and the sex ratio reversed for
carcinoids (0.5).
Among the 1,267 rectal cancers (676 males, incidence rate
14.6/100,000; 591 females, incidence rate 9.3/100,000), 75%
of cases in males and 65% in females were adenocarcinomas,
and a further 16% in both sexes were adenocarcinomas in
polyps or polyposis. Much more frequent in females that in
males were squamous cell (7.1 vs 1.9% in males) and transi-
tional cell cancers (5.9% vs 0.9%). Therefore the sex ratio
was relatively high for adenocarcinomas (1.8) but below 1 for
squamous and transitional cell cancers (0.5 and 0.2, respec-
tively).
An appreciable proportion of the 357 liver cancers (over
25% in males and 40% in females) were purely clinical or
of unspecified histotypes; among the histologically defined
cancers, 66% in males and 38% in females were hepatocellu-
lar carcinomas, 9% in males and 22% in females cholangio-
or combined hepato- cholangiocellular carcinomas. The
overall age-adjusted incidence was 5.9/100,000 males and
1.2/100,000 females. The sex ratio for the predominant mor-
phological type (i.e., hepatocellular) was 9.8, the highest
herein recorded. A 2.5-fold male excess emerged also for
cholangiocellular carcinomas, at variance with the female
excess in gallbladder carcinomas.
The large majority of gallbladder cancer (328 cases, 102
males and 226 females, with incidence rates of 2.2 and 3.1/
100,000, respectively) were adenocarcinomas (252 cases).
There were only two histologically confirmed squamous cell
carcinomas, and 74 other or undefined types. The sex ratioMORPHOLOGY OF DIGESTIVE CANCERS 569
Table II Number ofregistered cases, proportions, age-standardised incidence ratesa and sex ratios ofdigestive cancers according to primary
site, morphologic type and sex. (Vaud, Switzerland, 1976-1987)
Males Females Total
Site Sex ratio
Morphology No (%) Incidence' No (%) Incidence0 No (%) (MIF)
Mouth or pharynx (ICD-9: 140-149)
Squamous cell
Adenocarcinoma
Other carcinoma
Sarcoma
Lymphoma
Other or undefined
Total
Oesophagus (ICD-9:. 150)
Squamous cell
Adenocarcinoma
Other carinoma
Other or undefined
Total
Stomach (ICD-9: 151)
Adenocarcinoma
Other carcinoma
Sarcoma
Lymphoma
Other or undefined
Total
Small intestine (ICD-9: 152)
Adenocarcinoma
Carcinoid
Sarcoma
Lymphoma
Other or undefined
Total
Colon (ICD-9: 153)
Adenocarcinoma
Adenocarcinoma in polyp/polyposis
Other carcinoma
Carcinoid
Other or undefined
Total
Rectum (ICD-9: 154)
Adenocarcinoma
Adenocarcinoma in polyp/polyposis
Squamous cell
Transitional cell
Other or undefined
Total
Liver (ICD-9: 155)
Hepatocellular carcinoma
Cholangiocellular and combined
carcinoma
Other or undefined
Total
Gallbladder (ICD-9: 156)
Adenocarcinoma
Squamous cell
Other carcinoma
Other or undefined
Total
Pancreas (ICD-9: 157)
Adenocarcinoma
Islet cell carcinoma
Other carcinoma
Other or undefined
Total
721 (87.3)
7 (0.8)
38 (4.6)
7 (0.8)
14 (1.7)
39 (4.7)
826 (100.0)
283 (71.3)
48 (12.1)
23 (5.8)
43 (10.8)
397 (100.0)
595 (83.9)
24 (3.4)
5 (0.7)
34 (4.8)
51 (7.2)
709 (100.0)
15 (33.3)
13 (28.9)
3 (6.7)
12 (26.7)
2 (4.4)
45 (100.0)
837 (88.9)
30 (3.2)
12 (1.3)
5 (0.5)
57 (6.1)
941 (100.0)
508 (75.1)
115 (17.0)
13 (1.9)
6 (0.9)
34 (5.0)
676 (100.0)
183 (65.8)
24 (8.6)
71 (25.5)
278 (100.0)
78 (76.5)
-(-)
5 (4.9)
19 (18.6)
102 (100.0)
226 (58.4)
7 (1.8)
31 (8.0)
123 (31.8)
387 (100.0)
'Age-standardised rates on the World standard population.
17.4
0.1
0.9
0.2
0.3
0.8
19.8
6.2
1.1
0.5
1.1
8.9
12.7
0.5
0.1
0.8
1.2
15.4
0.3
0.3
0.1
0.3
0.05
1.0
17.5
0.6
0.3
0.1
1.4
20.0
10.9
2.5
0.3
0.1
0.7
14.6
3.9
0.5
1.5
5.9
1.7
0.1
0.4
2.2
4.9
0.2
0.6
2.8
8.5
160 (74.4) 2.9 881 (84.6) 6.0
3 (1.4) 0.04 10 (1.0) 2.5
12 (5.6) 0.2 50 (4.8) 4.2
2 (0.9) 0.1 9 (0.4) 2.0
14 (6.5) 0.2 28 (2.7) 1.3
24 (11.2) 0.4 63 (6.1) 1.9
215 (100.0) 3.8 1041 (100.0) 5.2
112 (75.7) 1.9
9 (6.1) 0.1
6 (4.1) 0.1
21 (14.2) 0.3
148 (100.0) 2.4
395 (72.5) 3.3
57 (10.5) 11.0
29 (5.3) 5.0
64 (11.7) 3.7
545 (100.0) 3.7
319 (75.6) 4.5 914 (80.8) 2.8
14 (3.3) 0.2 38 (3.4) 2.5
5 (1.2) 0.1 10 (0.9) 1.0
27 (6.4) 0.4 61 (5.4) 2.0
57 (13.5) 0.7 108 (9.5) 1.7
422 (100.0) 6.0 1131 (100.0) 2.6
11 (28.9) 0.1
13 (34.2) 0.2
5 (13.2) 0.1
5 (13.2) 0.1
4 (10.5) 0.05
38 (100.0) 0.5
26 (31.3) 3.0
26 (31.3) 1.5
8 (9.6) 1.0
17 (20.5) 3.0
6 (7.2) 1.0
83 (100.0) 2.0
913 (87.9) 13.0 1750 (88.4) 1.3
26 (2.5) 0.5 56 (2.8) 1.2
15 (1.4) 0.2 27 (1.4) 1.5
7 (0.7) 0.2 12 (0.6) 0.5
78 (7.5) 1.1 135 (6.8) 1.2
1039 (100.0) 14.9 1980 (100.0) 1.2
383 (64.8) 6.0 891 (70.3) 1.8
83 (14.0) 1.4 198 (15.6) 1.8
42 (7.1) 0.6 55 (4.3) 0.5
35 (5.9) 0.6 41 (3.2) 0.2
48 (8.1) 0.7 82 (6.5) 1.0
591 (100.0) 9.3 1267 (100.0) 1.6
30 (38.0) 0.4
17 (21.5) 0.2
32 (40.5) 0.5
79 (100.0) 1.2
213 (59.7) 9.8
41 (11.5) 2.5
103 (28.9) 3.0
357 (100.0) 4.9
174 (77.0) 2.4 252 (76.8) 0.7
2 (0.9) 0.04 2 (0.6) -
9 (4.0) 0.1 14 (4.3) 1.0
41 (18.1) 0.6 60 (18.3) 0.7
226 (100.0) 3.1 328 (100.0) 0.7
186 (55.0) 3.0
4 (1.2) 0.1
16 (4.7) 0.2
132 (39.1) 1.7
338 (100.0) 5.1
412 (56.8) 1.6
11 (1.5) 2.0
47 (6.5) 3.0
255 (35.2) 1.6
725 (100.0) 1.7
indicates, for adenocarcinomas and overall, 30% lower inci-
dence rates in males as compared to females.
Like in liver cancer, an appreciable proportion (over 30%)
of the 725 pancreatic cancer cases were morphologically
undefined. Among the histologically defined cases, 57% were
adenocarcinomas and 2% islet cell carcinomas, these propor-
tions being comparable in the two sexes. The age-standard-
ised incidence rates were 8.5/100,000 males and 5.1/100,000
females. The category 'other carcinoma' showed the highest
male-to-female ratio (3.0) whereas globally it was 1.7, the
third lowest after cancers of the gallbladder and colon.
Comparable figures in two separate strata of age (under 60
and 60 and over) are given in Table III. Besides some
systematic and probably real differences (i.e., lymphomas and
sarcomas were proportionally more common in younger and
middle ages as compared to older age), there was some
apparent heterogeneity, which however can be attributed to
more accurate case ascertainment in the young. This applies570 F. LEVI et al.
Table III Number of registered cases, proportions and age-standardised incidence ratesa of digestive
cancers according to primary site, morphologic type and age group. (Vaud, Switzerland, 1976-1987)
Site Age<60 Age>60
Morphology No (%) Incidencea No (%) IncidenceY
Mouth orpharynx (ICD-9: 140-149)
Squamous cell
Adenocarcinoma
Other carcinoma
Sarcoma
Lymphoma
Other or undefined
Total
Oesophagus (ICD-9: 150)
Squamous cell
Adenocarcinoma
Other carcinoma
Other or undefined
Total
Stomach (ICD-0: 151)
Adenocarcinoma
Other carcinoma
Sarcoma
Lymphoma
Other or undefined
Total
Small intestine (ICD-9: 152)
Adenocarcinoma
Carcinoid
Sarcoma
Lymphoma
Other or undefined
Total
Colon (ICD-9: 153)
Adenocarcinoma
Adenocarcinoma in polyp/polyposis
Other carcinoma
Carcinoid
Other or undefined
Total
Rectum (ICD-9: 154)
Adenocarcinoma
Adenocarcinoma in polyp/polyposis
Squamous cell
Transitional cell
Other or undefined
Total
Liver (ICD-9: 155)
Hepatocellular carcinoma
Cholangiocellular and combined
carcinoma
Other or undefined
Total
Gallbladder (ICD-9: 156)
Adenocarcinoma
Squamous cell
Other carcinoma
Other or undefined
Total
Pancreas (ICD-9: 157)
Adenocarcinoma
Islet cell carcinoma
Other carcinoma
Other or undefined
Total
aOn the World standard population.
527
3
22
6
12
27
597
167
20
6
9
202
258
7
8
29
11
313
8
5
S
8
3
29
438
26
7
9
11
491
271
58
18
16
7
370
71
10
26
107
53
4
14
71
146
5
16
43
210
(88.3)
(0.5)
(3.7)
(1.0)
(2.0)
(4.5)
(100.0)
(82.7)
(9.9)
(3.0)
(4.4)
(100.0)
(82.4)
(2.2)
(2.5)
(9.3)
(3.5)
(100.0)
(27.6)
(17.2)
(17.2)
(27.6)
(10.3)
(100.0)
(89.2)
(5.3)
(1.4)
(1.8)
(2.2)
(100.0)
(73.2)
(15.7)
(4.9)
(4.3)
(1.9)
(100.0)
(66.3)
(9.3)
(24.3)
(100.0)
(74.6)
(5.6)
(19.7)
(100.0)
(69.5)
(2.4)
(7.6)
(20.5)
(100.0)
7.3
0.0
0.3
0.1
0.2
0.4
8.3
2.3
0.3
0.1
0.1
2.7
3.5
0.1
0.1
0.4
0.1
4.3
0.1
0.1
0.1
0.1
0.0
0.4
6.0
0.4
0.1
0.2
0.2
6.7
3.7
0.8
0.2
0.2
0.1
5.0
0.9
0.1
0.4
1.5
0.7
0.1
0.2
1.0
2.0
0.1
0.2
0.6
2.8
354
7
28
3
16
36
444
228
37
23
55
343
656
31
2
32
97
818
(79.7)
(1.6)
(6.3)
(0.7)
(3.6)
(8.1)
(100.0)
(66.5)
(10.8)
(6.7)
(16.0)
(100.0)
(80.2)
(3.8)
(0.2)
(3.9)
(11.9)
(100.0)
18 (33.3)
21 (38.9)
3 (5.5)
9 (16.7)
3 (5.5)
54 (100.0)
1312 (88.1)
30 (2.0)
20 (1.3)
3 (0.2)
124 (8.3)
1489 (100.0)
620 (69.1)
140 (15.6)
37 (4.1)
25 (2.8)
75 (8.4)
897 (100.0)
142 (56.8)
31 (12.4)
77 (30.8)
250 (100.0)
199
2
10
46
257
266
6
31
212
515
(77.4)
(0.8)
(3.9)
(17.9)
(100.0)
(51.6)
(1.2)
(6.0)
(41.2)
(100.0)
to the smaller proportion under age 60 of other and un-
specified morphological types for all cancer sites but, most
notably, for liver and pancreas, and, possibly to the higher
frequency of adenocarcinomas arising on polyps in the colon
(but not in the rectum).
More detailed incidence rates for the different groups of
gender and decade of age are compared in two cancer sites:
colon and rectum (Table IV). Colon cancer rates in females
are similar to those in men up to age 45 and show a 30% to
50% preponderance in subsequent age groups. In relation to
rectal cancer, no consistent difference between sexes was
observed up to age 54, but male rates were appreciably
higher (60 to 100%) at older ages.
Five-year survival rates per each separate cancer site and
histotype are given in Table V. For oral cavity and, chiefly,
stomach cancer, sarcomas and lymphomas tended to have
better survival rates than carcinomas, but no systematic
difference was observed for various morphological types
39.4
0.6
2.9
0.3
1.6
3.8
8.7
24.7
4.1
2.9
6.6
8.3
68.0
3.0
0.3
3.2
11.3
85.7
1.8
2.2
0.3
0.8
0.2
5.3
134.1
3.0
2.2
0.3
14.8
154.4
65.6
15.4
3.9
2.6
8.7
96.2
15.0
3.1
8.2
26.4
20.5
0.3
0.9
4.6
26.4
28.8
0.6
3.0
23.0
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Table IV Age- and sex-specific incidence rates' and male-to-female
ratios for cancers of the colon and rectum (Vaud, Switzerland,
1976-1987)
Age (years)
Cancersite Gender <45 45-5455-6465-74 75
Colon Males 1.19 18.67 54.04 126.77 320.30
(ICD-9: 153) Females 1.23 14.89 35.50 88.92 256.03
Male-to-female ratio 0.97 1.25 1.52 1.43 1.25
Rectum Males 0.76 11.53 42.50 99.22 218.37
(ICD-9: 154) Females 0.46 15.67 27.12 50.44 128.16
Male-to-female ratio 1.65 0.74 1.57 1.97 1.70
'Age-standardised rates on the World standard population.
within carcinomas. Cases of small intestinal cancer had 5-
year survival rates only marginally different (29%) from
those of colon (34%) and rectum (37%), with similar rates
for infiltrating carcinoids and adenocarcinomas. In the colon
higher survival rates were observed for carcinoids (92%) and
adenocarcinomas in polyps or polyposis (57%). In the rec-
tum, too, survival rates were higher for cancers arising in
polyps (53%), but no appreciable difference was observed
between adenocarcinomas (35%), squamous (46%) or transi-
tional cell carcinomas. Survival was extremely poor (under
10% at 5 years) for all cancers arising in the liver, gallblad-
der and pancreas, with the sole exception of the few islet cell
carcinomas of the pancreas (34% 5 year rate).
Discussion
The present report has essentially a descriptive value, since it
adds more detailed population-based information on inci-
dence and survival rates than commonly available from
cancer registration schemes. Most of its findings are already
well recognised (Faivre et al., 1979a,b; Weber et al., 1980;
Widgren, 1980; Blenkisopp et al., 1981; Levine et al., 1981;
Mittal et al., 1983; Faivre et al., 1985; Cherie-Challine et al.,
1988; Yang et al., 1988; Kimura et al., 1989), and this article
should essentially be viewed as a contribution towards the
quantification, in a well surveilled population of the West-
central part of Europe, of the proportional distribution of
digestive neoplasms by morphological type, and correspond-
ing incidence and survival rates. The high population cover-
age represents a major originality and reason of interest of
the present study, although the accuracy of pathological
diagnoses may be less precise than in some selected patho-
logical series.
Like in some nearby countries (i.e., France and Italy; Muir
et al., 1987; Levi et al., 1989), where the prevalence of
smoking and high alcohol intake is elevated, cancers of the
upper digestive tract (i.e., mouth, pharynx and oesophagus)
represent in the Registry of Vaud a high fraction of digestive
tract neoplasms (28% in males, 11% in females). Indeed, in
comparison with 44 other European cancer registration areas
(Levi et al., 1989), incidence rates for cancers of the oral
cavity and pharynx, and oesophagus rank seven and five,
respectively, in males and six and 16 in females. The other
digestive cancers are situated, in the European range, at
intermediate-high levels, whereas incidence from gastric
cancer is among the lowest in both sexes (Levi et al., 1989).
The site-specific sex ratios of mortality in Switzerland have
already been reviewed (La Vecchia & Levi, 1988) and also
here do not differ substantially from other European count-
ries (Levi et al., 1989) (with the possible exception of a
particularly notable male excess in gastric cancer incidence).
A careful assessment of different morphological types, how-
ever, reveals some still largely unappreciated features. The
highest male-to-female ratios are found in squamous cell
carcinomas of the mouth and pharynx, adenocarcinomas of
the oesophagus, and hepatocellular carcinomas, the lowest
ones not only in infiltrating carcinoids of the colon and
gallbladder adenocarcinomas, in which a female excess is well
TableV Product-limit survival ratesfordigestivecancersaccordingto
primary site and morphologic type. (Vaud, Switzerland, 1976-1987)
Site 5-year survival
Morphology Probability (SE)'
Mouth orpharynx (ICD-9: 140-149)
Squamous cell
Adenocarcinoma
Other carcinoma
Sarcoma
Lymphoma
Other or undefined
Total
Oesophagus (ICD-9: 150)
Squamous cell
Adenocarcinoma
Other carcinoma
Other or undefined
Total
Stomach (ICD-9: 151)
Adenocarcinoma
Other carcinoma
Sarcoma
Lymphoma
Other or undefined
Total
Small intestine (ICD-9: 152)
Adenocarcinoma
Carcinoid
Sarcoma
Lymphoma
Other or undefined
Total
Colon (ICD-9: 153)
Adenocarcinoma
Adenocarcinoma in polyp/polyosis
Other carcinoma
Carcinoid
Other or undefined
Total
Rectum (ICD-9: 154)
Adenocarcinoma
Adenocarcinoma in polyp/polyosis
Squamous cell
Transitional cell
Other or undefined
Total
Liver (ICD-9: 155)
Hepatocellular carcinoma
Cholangiocellular and combined
carcinoma
Other or undefined
Total
Gallbladder (ICD-9: 156)
Adenocarcinoma
Squamous cell
Other carcinoma
Other or undefined
Total
0.31
0.57
0.30
0.56
0.48
0.40
0.32
0.05
0.07
0.07
0.02
0.05
0.17
0.03
0.40
0.61
0.09
0.18
0.36
0.34
[O.16]b
[0.18]
[0.17]
0.29
0.38
0.57
0.31
0.92
[0.01]
0.34
0.35
0.53
0.46
0.41
[0.02]
0.37
[0.01]
[0.02]
[0.02]
0.01
0.09
0.14
[0.05]
0.07
(0.02)"
(0.16)
(0.07)
(0.17)
(0.13)
(0.06)
(0.02)
(0.01)
(0.03)
(0.05)
(0.02)
(0.01)
(0.01)
(0.03)
(0.15)
(0.07)
(0.02)
(0.01)
(0.10)
(0.10)
(0.14)
(0.11)
(0.15)
(0.05)
(0.01)
(0.07)
(0.04)
(0.08)
(0.01)
(0.01)
(0.02)
(0.04)
(0.08)
(0.08)
(0.02)
(0.01)
(0.02)
(0.02)
(0.01)
(0.01)
(0.02)
(-)
(0.09)
(0.03)
(0.02)
Pancreas (ICD-9: 157)
Adenocarcinoma 0.01 (0.005)
Islet cell carcinoma 0.34 (0.15)
Other carcinoma [0.11] (0.04)
Other or undefined 0.02 (0.01)
Total 0.01 (0.004)
'Standard error(s.e.) shown within parentheses.bEstimates based on
less than five cases at the end of the interval are shown in square
brackets.
recognised (Muir et al., 1987; Peter et al., 1990), but also in
transitional and squamous cell carcinomas of the rectum.
Although drawing aetiological conclusions remains difficult
(e.g., involvement of squamous-cell tropic viruses common in
the female low genital tract, such as papillomavirus; Zur
Hausen, 1989), it is, in any case, worth noting that the
male-to-female ratio in squamous cell cancers shows a tend-
ency to decrease along the digestive tract: from 6.0 in the
oral cavity and pharynx to 0.5 in the rectum.572 F. LEVI et al.
Age-specific incidence rates of colon cancer for Caucasian
women are generally equal or higher than those for men
before the sixth decade, after which the rates for men exceed
those for women (McMichael & Potter, 1980; Faivre et al.,
1989; Zaridze & Filipchenko, 1990; Peters et al., 1990). Kune
et al. (1986) developed regression log-linear models to
analyse the relationship between sex and incidence rates for
five colorectal subsites, and suggested that the increasing
male-to-female ratio with the increasing distance down the
large bowel is related to the earlier age at which the male
excess occurs the further the distance down the bowel.
Although utmost caution is suggested by the difficulties in
classifying bowel cancer subsites correctly, data from the
Registry of Vaud support the possibility that the male excess
is greater for rectal cancer at older ages.
Besides the descriptive aspects, there are a few points
which deserve specific attention. Among these, there is the
confirmation of higher survival rates of lymphomas as com-
pared to carcinomas of the stomach and, perhaps, of the oral
cavity (Mittal et al., 1983); among small bowel cancers, the
proportion of infiltrating carcinoids is similar to that of
adenocarcinomas and the survival rate for these two histo-
types is comparable (approximately 35% at 5 years); overall,
survival from small bowel cancers (29% at 5 years) is only
slightly lower than for the globality of colon (34%) or rectal
(37%) cancers. In relation to large bowel cancers, survival
was, as expected, higher for carcinomas arising on polyps,
but there is, to our knowledge, no simple explanation for the
larger proportion of squamous and transitional cell cancers
in females (although this has not important prognostic imp-
lications).
The elevated proportion of undefined histological types for
liver and pancreatic cancers underlines the difficulties of
precise case ascertainment and classification for these neo-
plasms (Doll & Peto, 1981), even in a highly integrated and
monitored population-based scheme.
The higher frequency of cholangio- and hepatocellular car-
cinomas combined in females than in males probably reflects
similarities of aetiological correlates with gallbladder cancer,
although the issue is still discussed (Strom et al., 1985),
Prognosis was extremely poor for all neoplasms arising from
liver, gallbladder and pancreas (Propok, 1978; Levine et al.,
1981; Doll & Peto, 1981; Cairns & Boyle, 1983; American
Cancer Society, 1988), but there was some suggestion that
intrahepatic cholangiocellular carcinomas have lower survival
than gallbladder cancers.
These and several other indications emerging from careful
examination of the data presented herein underline the
interest of morphological analyses of digestive tract neo-
plasms, in terms of descriptive epidemiology, inference on
aetiological correlates and prognostic implications.
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